The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
AM23-SN-02-O: Navigating the FDA Licensure Pathway (Enduring)
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$3000
Standard Price
Members save $5
This session will review the steps required when applying to the Food and Drug Administration (FDA) for an original Biologics License Application (BLA) to manufacture, modify, market and distribute blood components and biologics in interstate commerce. An overview of the initial submission requirements will be provided. Changes to an approved application which require supplemental reporting including labeling, production processes, quality control, equipment and facilities will be outlined. The change reporting parameters, requisite materials and implementation time frames for Changes being Effected (CBE and CBE30) or Prior Approval Supplement (PAS) will be discussed. The applicability and content of a comparability protocol for submitting an alternate procedure will be described along with the implementation timeframes. The Annual Reporting (AR) obligations to FDA for licensed facilities will be defined. The pathways available to submit these various applications and supplements will be examined along with a demonstration of the sign-on and navigation of the FDA electronic submission process. Lessons learned through these various application processes will be shared to help streamline the learning curve for new submitters. If you’re just starting down the FDA registration and licensing pathway or a seasoned navigator hoping to avoid inadvertently taking the wrong fork in the road, this session is for you!
Learning Objectives
Understand Biological License Application (BLA) contents and the BLA review process.
Discuss labeling, production process, quality control, equipment and facility changes that must be reported to FDA.
Categorize the three reporting categories for changes to an approved application.
Identify the time frames for the different reporting categories.
Summarize the methods to be used to submit and amend a Biologics license.
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM23-SN-02-O: Navigating the FDA Licensure Pathway (Enduring) Evaluation
In today’s rapidly evolving healthcare environment, understanding the latest policy developments is crucial for strategic planning and operational success. This session will explore the significant implications of the recent Supreme Court decision – Loper Bright Enterprises v…
The future of the blood and biotherapies fields depends on our ability to prepare a new generation of leaders and skilled professionals to continue advancing the field…
Many blood operators around the world are implementing individualized donor assessments that welcome more trans, non-binary, and gender-diverse people to donate…